Table 3. Survival analysis of RFS and OS.
| Parameters | N | RFS rates (%) | OS rates (%) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1-year | 3-year | 5-year | P | 1-year | 3-year | 5-year | P | |||
| Total | 94 | 84.0 | 63.1 | 54.6 | 96.7 | 78.9 | 68.7 | |||
| Primary site | 0.584 | 0.880 | ||||||||
| Left colon | 25 | 88 | 73 | 56.9 | NR | 80.7 | 69.2 | |||
| Right colon | 36 | 83.3 | 50.4 | 50.4 | 91.7 | 77.3 | 64.9 | |||
| Rectum | 33 | 81.8 | 68 | 56.7 | 97 | 79 | 70.7 | |||
| N stage* | 0.042 | 0.097 | ||||||||
| Negative | 31 | 96.8 | 80.3 | 61.8 | 96.8 | 92.9 | 78.4 | |||
| Positive | 52 | 78.8 | 51.9 | 48.2 | 96.1 | 70.8 | 64.4 | |||
| Time of metastasis | 0.78 | 0.800 | ||||||||
| Metachronous | 40 | 77.5 | 65.5 | 60.1 | 95 | 83 | 70.2 | |||
| Synchronous | 54 | 88.9 | 61.4 | 50.6 | 96.3 | 75.5 | 67.8 | |||
| Size of metastasis | 0.842 | 0.525 | ||||||||
| >3 | 24 | 75 | 65.6 | 56.2 | 91.7 | 77.9 | 64.3 | |||
| ≤3 | 70 | 87.1 | 62.2 | 53.8 | 97.1 | 79.1 | 70.2 | |||
| CEA** | 0.091 | 0.158 | ||||||||
| >3 | 33 | 93.9 | 78.5 | 60.0 | 97 | 84.4 | 76.7 | |||
| ≤3 | 56 | 78.6 | 57 | 53.4 | 94.6 | 75.7 | 69.0 | |||
| Postoperative chemotherapy | 0.362 | 0.837 | ||||||||
| No | 33 | 93.9 | 72.3 | 60.2 | 97 | 85 | 65.4 | |||
| Yes | 61 | 78.7 | 58.9 | 51.1 | 95 | 76.2 | 68.6 | |||
| CD8+ TIL | 0.018 | 0.102 | ||||||||
| Low | 51 | 74.5 | 55.3 | 46.2 | 92.1 | 76 | 62.6 | |||
| High | 43 | 95.3 | 71.6 | 65.1 | NR | 82 | 77.4 | |||
| PD-L1+ cells | <0.001 | <0.001 | ||||||||
| Low | 47 | 93.6 | 88.6 | 83.9 | 95.7 | 92.9 | 86.1 | |||
| High | 47 | 74.5 | 38.4 | 26.6 | 95.7 | 65 | 50.3 | |||
| CD8-PDL1 | <0.001 | <0.001 | ||||||||
| Strong | 24 | NR | 89.5 | 89.5 | NR | 93.8 | 85.2 | |||
| Mild | 42 | 88.1 | 71.7 | 63.7 | 95.2 | 81.8 | 78.4 | |||
| Weak | 28 | 64.3 | 28.8 | 17.3 | 92.9 | 61.6 | 38.0 | |||
*, available for 83 patients; **, available for 89 patients. CEA, carcinoembryonic antigen; TIL, tumor infiltrating lymphocytes; CD8-PDL1, combination of CD8 TIL and PD-L1 expression.